百济神州
ONC301.130USD
+1.190+0.40%
收盘 07/31, 16:00（美东）报价延迟15分钟
29.84B总市值
亏损市盈率 TTM
关于 Beigene Ltd 公司
百济神州有限公司是一家全球生物科技公司，致力于为全球癌症患者发现和开发肿瘤治疗药物。该公司已发现和开发了三种获批药物，包括 BRUKINSA，一种用于治疗各种血癌的布鲁顿酪氨酸激酶小分子抑制剂；TEVIMBRA（替雷利珠单抗），一种用于治疗各种实体瘤和血癌的抗 PD-1 抗体免疫疗法；以及帕米帕尼，一种选择性聚 ADP-核糖聚合酶 1 (PARP1) 和 PARP2 小分子抑制剂。该公司已获准在美国、中华人民共和国（中国）、欧盟、英国、加拿大、澳大利亚和其他国际市场销售 BRUKINSA；在欧盟和中国销售替雷利珠单抗；在中国销售帕米帕尼。该公司还专注于在安进公司 (Amgen Inc.) 的独家许可下在中国商业化 XGEVA、BLINCYTO、KYPROLIS 等抗癌药物。
公司简介
公司代码ONC
公司名称Beigene Ltd
上市日期- -
成立日期2025
CEOMr. John Victor Oyler
员工数量11000
证券类型Ordinary Share
年结日- -
公司地址c/o BeOne Medicines I GmbH
城市BASEL
上市交易所The Toronto Stock Exchange
国家Switzerland
邮编4051
电话41616851900
网址
公司代码ONC
上市日期- -
成立日期2025
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
-33.42%
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
-33.42%
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
Other
-1.03B
-92.23%
地区USD
名称
营收
占比
United States
567.21M
50.77%
China
399.59M
35.76%
Europe
118.55M
10.61%
ROW
31.92M
2.86%
业务
地区
业务USD
名称
营收
占比
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
Other
-1.03B
-92.23%
股东统计
更新时间: 10 小时前
更新时间: 10 小时前
持股股东
股东类型
持股股东
持股股东
占比
Amgen Inc
17.28%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.64%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.12%
持股股东
持股股东
占比
Amgen Inc
17.28%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.64%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.12%
股东类型
持股股东
占比
Investment Advisor
21.72%
Corporation
17.29%
Hedge Fund
10.90%
Investment Advisor/Hedge Fund
4.72%
Sovereign Wealth Fund
1.32%
Research Firm
0.89%
Pension Fund
0.21%
Bank and Trust
0.11%
Family Office
0.02%
Other
42.81%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
556
67.06M
61.19%
+4.46M
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Amgen Inc
18.94M
17.28%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.03%
--
--
Mar 31, 2025
Capital International Investors
5.09M
4.64%
-1.02M
-16.72%
Mar 31, 2025
PRIMECAP Management Company
5.06M
4.61%
-43.40K
-0.85%
Mar 31, 2025
Baillie Gifford & Co.
3.63M
3.31%
-40.48K
-1.10%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.36M
3.07%
+1.58M
+88.38%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.41M
1.29%
-80.54K
-5.39%
Mar 31, 2025
T. Rowe Price International Ltd
1.30M
1.19%
-143.22K
-9.92%
Mar 31, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
May 09, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
First Trust NYSE Arca Biotechnology Index Fund
3.35%
Tema Oncology ETF
2.71%
VanEck Biotech ETF
2.17%
Global X Aging Population ETF
1.94%
Virtus LifeSci Biotech Products ETF
1.74%
iShares Health Innovation Active ETF
1.43%
iShares Biotechnology ETF
1.42%
Invesco Nasdaq Biotechnology ETF
1.15%
ProShares Ultra Nasdaq Biotechnology
1.14%
National Security Emerging Markets Index ETF
0.68%
查看更多
First Trust NYSE Arca Biotechnology Index Fund
占比3.35%
Tema Oncology ETF
占比2.71%
VanEck Biotech ETF
占比2.17%
Global X Aging Population ETF
占比1.94%
Virtus LifeSci Biotech Products ETF
占比1.74%
iShares Health Innovation Active ETF
占比1.43%
iShares Biotechnology ETF
占比1.42%
Invesco Nasdaq Biotechnology ETF
占比1.15%
ProShares Ultra Nasdaq Biotechnology
占比1.14%
National Security Emerging Markets Index ETF
占比0.68%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
